Intellia Therapeutics (NTLA) Misses Q3 EPS by 20c

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.49), $0.20 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $13.27 million versus the consensus estimate of $11.43 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Morgan Stanley upgrades CDW on stronger AI-driven server demand